Telesis Bio, Inc. (TBIO)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Nov 4, 2025, 12:23 PM EST
Telesis Bio Revenue
Telesis Bio had revenue of $1.57M in the quarter ending September 30, 2024, a decrease of -61.79%. This brings the company's revenue in the last twelve months to $17.03M, down -32.54% year-over-year. In the year 2023, Telesis Bio had annual revenue of $27.51M with 0.27% growth.
Revenue (ttm)
17.03M
Revenue Growth
-32.54%
P/S Ratio
0.00
Revenue / Employee
436.77K
Employees
39
Market Cap
180.00
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 27.51M | 74.00K | 0.27% |
| Dec 31, 2022 | 27.44M | 16.39M | 148.44% |
| Dec 31, 2021 | 11.04M | 4.47M | 67.93% |
| Dec 31, 2020 | 6.58M | 810.00K | 14.05% |
| Dec 31, 2019 | 5.77M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ViewRay Systems | 105.86M |
| Avitar | 2.66M |
| Lattice Biologics | 1.56M |
| Enchanted World | 303.00K |
| Brain Scientific | 214.56K |
| Zecotek Photonics | 141.07K |
Telesis Bio News
- 8 months ago - Telesis Bio Slides: Investor presentation - Filings
- 1 year ago - Telesis Bio, Regeneron partner for rapid DNA, gene synthesis - TheFly
- 1 year ago - Telesis Bio Quarterly report: Q3 2024 - Filings
- 2 years ago - Telesis Bio and Beckman Coulter team to enable ‘breakthrough’ discoveries - TheFly
- 2 years ago - Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis - GlobeNewsWire
- 2 years ago - Biotech Alert: Searches spiking for these stocks today - TheFly
- 2 years ago - Telesis Bio to delist shares from Nasdaq - TheFly
- 2 years ago - Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market - GlobeNewsWire